Wedbush reiterated their outperform rating on shares of ARGENX SE-ADR (NASDAQ:ARGX) in a research report sent to investors on Thursday, The Fly reports. They currently have a $41.00 price target on the stock, up from their previous price target of $26.00. The analysts noted that the move was a valuation call.

A number of other analysts have also commented on the stock. Zacks Investment Research lowered shares of ARGENX SE-ADR from a buy rating to a hold rating in a research note on Wednesday, October 25th. Cowen and Company restated a buy rating on shares of ARGENX SE-ADR in a research note on Thursday, August 24th.

ARGENX SE-ADR (ARGX) traded down $0.15 during trading on Thursday, hitting $24.19. 23,278 shares of the company were exchanged, compared to its average volume of 52,639. ARGENX SE-ADR has a 52 week low of $17.33 and a 52 week high of $27.25.

ILLEGAL ACTIVITY NOTICE: “ARGENX SE-ADR (ARGX) Earns “Outperform” Rating from Wedbush” was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international copyright laws. The legal version of this story can be accessed at https://www.thecerbatgem.com/2017/11/19/argenx-se-adr-argx-earns-outperform-rating-from-wedbush.html.

Hedge funds have recently made changes to their positions in the business. Nicholas Investment Partners LP bought a new stake in ARGENX SE-ADR during the 2nd quarter valued at $236,000. DAFNA Capital Management LLC bought a new stake in shares of ARGENX SE-ADR in the 2nd quarter worth $848,000. Artal Group S.A. bought a new stake in shares of ARGENX SE-ADR in the 3rd quarter worth $1,229,000. Tekla Capital Management LLC bought a new stake in shares of ARGENX SE-ADR in the 2nd quarter worth $1,591,000. Finally, AWM Investment Company Inc. bought a new stake in shares of ARGENX SE-ADR in the 2nd quarter worth $2,121,000. Institutional investors and hedge funds own 24.69% of the company’s stock.

ARGENX SE-ADR Company Profile

argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company’s lead clinical stage product candidates include ARGX-113, a product in Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis and immune thrombocytopenia; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of hematological cancers, such as T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.

The Fly

Receive News & Stock Ratings for ARGENX SE-ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARGENX SE-ADR and related stocks with our FREE daily email newsletter.